HitGen（688222）株式概要ヒットジェン社は、低分子および核酸医薬の創薬研究プラットフォームとして、中国および国際的に事業を展開している。 詳細688222 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績5/6財務の健全性5/6配当金1/6報酬収益は年間21.72%増加すると予測されています 過去1年間で収益は86.8%増加しました リスク分析CN市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る688222 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,827 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,827 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥38.3931.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-6m1b2016201920222025202620282031Revenue CN¥1.2bEarnings CN¥256.2mAdvancedSet Fair ValueView all narrativesHitGen Inc. 競合他社GemPharmatechSymbol: SHSE:688046Market cap: CN¥16.4bSuzhou Sepax TechnologiesSymbol: SHSE:688758Market cap: CN¥12.2bShanghai Haoyuan ChemexpressSymbol: SHSE:688131Market cap: CN¥21.4bBeijing Sun-Novo Pharmaceutical ResearchSymbol: SHSE:688621Market cap: CN¥7.4b価格と性能株価の高値、安値、推移の概要HitGen過去の株価現在の株価CN¥38.3952週高値CN¥42.9852週安値CN¥21.46ベータ0.581ヶ月の変化29.26%3ヶ月変化33.76%1年変化66.70%3年間の変化169.78%5年間の変化n/aIPOからの変化118.75%最新ニュースお知らせ • Jun 30HitGen Inc. to Report First Half, 2026 Results on Aug 27, 2026HitGen Inc. announced that they will report first half, 2026 results on Aug 27, 2026New Risk • Jun 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 97% Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Declared Dividend • Jun 15Dividend increased to CN¥0.13Dividend of CN¥0.13 is 117% higher than last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 79% over the next 3 years, which should provide support to the dividend and adequate earnings cover.New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Xue Junfu was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29HitGen Inc., Annual General Meeting, May 29, 2026HitGen Inc., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 2F, Building C2, No. 18, Huigu Dongyi Road, Shuangliu District, Chengdu, Sichuan China最新情報をもっと見るRecent updatesお知らせ • Jun 30HitGen Inc. to Report First Half, 2026 Results on Aug 27, 2026HitGen Inc. announced that they will report first half, 2026 results on Aug 27, 2026New Risk • Jun 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 97% Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Declared Dividend • Jun 15Dividend increased to CN¥0.13Dividend of CN¥0.13 is 117% higher than last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 79% over the next 3 years, which should provide support to the dividend and adequate earnings cover.New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Xue Junfu was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29HitGen Inc., Annual General Meeting, May 29, 2026HitGen Inc., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 2F, Building C2, No. 18, Huigu Dongyi Road, Shuangliu District, Chengdu, Sichuan Chinaお知らせ • Mar 30HitGen Inc. to Report Q1, 2026 Results on Apr 29, 2026HitGen Inc. announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Dec 26HitGen Inc. to Report Fiscal Year 2025 Results on Apr 29, 2026HitGen Inc. announced that they will report fiscal year 2025 results on Apr 29, 2026お知らせ • Sep 30HitGen Inc. to Report Q3, 2025 Results on Oct 30, 2025HitGen Inc. announced that they will report Q3, 2025 results on Oct 30, 2025お知らせ • Aug 27HitGen Inc. Introduces OpenDEL™ 5.0HitGen Inc. is raising the bar with the introduction of OpenDEL™ 5.0 - featuring a total of 4 billion diverse compounds designed to tackle challenging biological targets. OpenDEL™ 5.,0 comes in a convenient kit format that is accessible to scientists in industry and academia alike. Key Improvements: Expanded Chemical Diversity: 4 billion Compounds; Increased Library Size: Now with 25% more compounds, OpenDEL™ 5.'0 offers 3.8 billion small molecules compounds and 200 million peptide compounds to further expand chemical space for targeting protein-protein-interactions (PPI). Encompassing Library Design: 59 distinct libraries provide a broad range of chemistries to address different types of targets and discovery challenges; Optional Macrocycle Library: Unlocking Challenging Targets; A dedicated macrocycle library: Available as an add-on, featuring 4-10 amino acids in the ring. Comes with a linear peptide control library; Dual-Kit Flexibility: Choose between OpenDEL™-Small Molecules or OpenDEL™-Macrocycle - or combine both for maximum coverage; Streamlined Workflow & Faster Access; Redesigned protocols: Intuitive visual guides simplify key steps, reducing onboarding time; Expedited delivery: Next-day shipping available to minimize wait time.お知らせ • Jun 30HitGen Inc. to Report First Half, 2025 Results on Aug 28, 2025HitGen Inc. announced that they will report first half, 2025 results on Aug 28, 2025お知らせ • Apr 26HitGen Inc., Annual General Meeting, May 23, 2025HitGen Inc., Annual General Meeting, May 23, 2025, at 14:30 China Standard Time. Location: 2F, Building C2, No. 18, Huigu East 1st Road, Shuangliu District, Chengdu, Sichuan Chinaお知らせ • Mar 28HitGen Inc. to Report Q1, 2025 Results on Apr 26, 2025HitGen Inc. announced that they will report Q1, 2025 results on Apr 26, 2025お知らせ • Dec 27HitGen Inc. to Report Fiscal Year 2024 Results on Apr 26, 2025HitGen Inc. announced that they will report fiscal year 2024 results on Apr 26, 2025New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.031 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.031 in 3Q 2023). Revenue: CN¥103.5m (up 15% from 3Q 2023). Net income: CN¥19.9m (up 60% from 3Q 2023). Profit margin: 19% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.Buy Or Sell Opportunity • Oct 22Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to CN¥12.32. The fair value is estimated to be CN¥10.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 19%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 56% in the next 2 years.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Sep 30HitGen Inc. to Report Q3, 2024 Results on Oct 26, 2024HitGen Inc. announced that they will report Q3, 2024 results on Oct 26, 2024Buy Or Sell Opportunity • Jul 31Now 20% overvaluedOver the last 90 days, the stock has fallen 24% to CN¥10.30. The fair value is estimated to be CN¥8.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 23%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 1.1% in the next 2 years.Buy Or Sell Opportunity • Jul 11Now 25% overvaluedOver the last 90 days, the stock has fallen 13% to CN¥10.84. The fair value is estimated to be CN¥8.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 23%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 1.1% in the next 2 years.お知らせ • Jun 29HitGen Inc. to Report First Half, 2024 Results on Aug 29, 2024HitGen Inc. announced that they will report first half, 2024 results on Aug 29, 2024お知らせ • Apr 26HitGen Inc., Annual General Meeting, May 22, 2024HitGen Inc., Annual General Meeting, May 22, 2024, at 14:30 China Standard Time. Location: 6F, No. 1166, Jiannan Avenue South Section, Shuangliu District, Chengdu, Sichuan ChinaReported Earnings • Apr 25First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.03 (up from CN¥0.02 loss in 1Q 2023). Revenue: CN¥107.4m (up 54% from 1Q 2023). Net income: CN¥13.9m (up CN¥23.3m from 1Q 2023). Profit margin: 13% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.お知らせ • Mar 29HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024HitGen Inc. announced that they will report Q1, 2024 results on Apr 25, 2024Buy Or Sell Opportunity • Mar 21Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at CN¥14.98. The fair value is estimated to be CN¥19.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has declined by 32%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 37% in the next 2 years.Reported Earnings • Feb 25Full year 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.06 in FY 2022)Full year 2023 results: EPS: CN¥0.11 (up from CN¥0.06 in FY 2022). Revenue: CN¥371.7m (up 13% from FY 2022). Net income: CN¥43.9m (up 74% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in China.Reported Earnings • Nov 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: CN¥90.1m (up 13% from 3Q 2022). Net income: CN¥12.5m (down 29% from 3Q 2022). Profit margin: 14% (down from 22% in 3Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Life Sciences industry in China.New Risk • Oct 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results.Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.022 (up from CN¥0 in 2Q 2022). Revenue: CN¥86.1m (up 30% from 2Q 2022). Net income: CN¥15.2m (up CN¥15.2m from 2Q 2022). Profit margin: 18% (up from 0% in 2Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in China.お知らせ • Jun 28HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023HitGen Inc. announced that they will report Q2, 2023 results on Aug 23, 2023お知らせ • Jun 27HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery ResearchHitGen Inc. has recently launched a newly upgraded version of its OpenDEL™? product, a self-service screening kit for novel molecules. It contains 65% more DEL libraries than the previous version, and with over 3 billion compounds. The 2-cycle and 3-cycle libraries in the kit are designed with excellent drug-like properties. The upgraded OpenDEL™? provides more diverse options with more flexible packages and service models to meet more differentiated user needs. OpenDEL™? is a self-service DNA-encoded library (DEL) kit, which enables users to explore DEL selection campaigns without revealing the target identity. Under the guidance of the manual and operating instructions, users can utilize OpenDEL™? to conduct affinity screening experiments against protein targets in their own laboratories. HitGen can provide upstream and downstream technical support. OpenDEL™? are a fully-open, transparent, small molecule screening kit, featuring complete disclosure of information for molecular structures, building blocks, scaffolds and compound encoding sequences. The users do not need to pay structure disclosure fees, nor compound IP license fees. OpenDEL™? can be widely applied in multiple areas, including drug discovery and AI-ML research. In the drug discovery scenarios, the complete information disclosure of OpenDEL™? can enable efficient and convenient discovery of novel hits and lead compounds. In the AI-ML scenarios, OpenDEL™? can provide a large number of high-quality screening data to facilitate the AI/ML predictive model building, algorithm development and validation, as well as other frontier explorations, thus promoting the AI-driven drug development. Since its release, OpenDEL™? has been widely used and highly recognized by many users from more than 10 countries, including biopharmaceutical companies, AI technology companies, academic institutions and colleges.Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.株主還元688222CN Life SciencesCN 市場7D5.5%4.3%2.0%1Y66.7%44.4%10.3%株主還元を見る業界別リターン: 688222過去 1 年間で44.4 % の収益を上げたCN Life Sciences業界を上回りました。リターン対市場: 688222過去 1 年間で10.3 % の収益を上げたCN市場を上回りました。価格変動Is 688222's price volatile compared to industry and market?688222 volatility688222 Average Weekly Movement11.1%Life Sciences Industry Average Movement9.9%Market Average Movement7.3%10% most volatile stocks in CN Market12.5%10% least volatile stocks in CN Market4.4%安定した株価: 688222の株価は、 CN市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 688222の weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてCNの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2012546Li Jinwww.hitgen.comHitGen社は、低分子および核酸医薬の創薬研究プラットフォームとして、中国国内外で事業を展開している。同社の技術プラットフォームには、DNAコード化ライブラリー技術、フラグメントベースの創薬技術、構造ベースのドラッグデザイン技術、合成治療用オリゴヌクレオチド技術の新興技術プラットフォーム、標的タンパク質分解技術などがある。同社の製品パイプラインには、多発性骨髄腫および固形がんを対象とした選択的HDAC阻害剤HG146、固形がんを対象とした第2世代NTRK/ROS1阻害剤錠HG030、がんを対象とした免疫腫瘍学アゴニストHG381、がんを対象とした腫瘍免疫学HGT01およびHGT02がある。さらに、がんを対象としたタンパク質分解薬HGT03、トランスクリプトミクスHGT04、肝臓がんを対象としたキナーゼ阻害薬HGT05、炎症を対象とした抗炎症治療薬の低分子化合物HGP0508、緑内障を対象としたキナーゼ阻害薬HGC245を提供している。核酸医薬パイプラインには、肝臓がんを対象としたTGF-β1特異的siRNA医薬HGP2142、がん標的の特異的変異を対象とした核酸医薬HGN001、固形がんを対象としたHGN002などがある。さらに、ターゲット検証、ヒット化合物の同定、ヒットからリードへの最適化、リードの最適化、前臨床試験およびIND、臨床開発、総合的な創薬サービスを提供している。さらに、同社は腫瘍学および免疫腫瘍学、炎症性疾患および自己免疫疾患、眼科学、感染症、代謝性疾患、心血管疾患に注力している。ヒットジェン社は2012年に設立され、中国の成都を拠点としている。もっと見るHitGen Inc. 基礎のまとめHitGen の収益と売上を時価総額と比較するとどうか。688222 基礎統計学時価総額CN¥15.38b収益（TTM）CN¥122.72m売上高(TTM)CN¥579.37m125.3xPER（株価収益率26.5xP/Sレシオ688222 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計688222 損益計算書（TTM）収益CN¥579.37m売上原価CN¥259.31m売上総利益CN¥320.06mその他の費用CN¥197.34m収益CN¥122.72m直近の収益報告Mar 31, 2026次回決算日Aug 27, 2026一株当たり利益（EPS）0.31グロス・マージン55.24%純利益率21.18%有利子負債／自己資本比率14.7%688222 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.3%現在の配当利回り43%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 06:11終値2026/08/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HitGen Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Jin ZhangChina International Capital Corporation LimitedXibing ChenGuosen Securities Co., Ltd.Hanyang HuangIndustrial Securities Co. Ltd.1 その他のアナリストを表示
お知らせ • Jun 30HitGen Inc. to Report First Half, 2026 Results on Aug 27, 2026HitGen Inc. announced that they will report first half, 2026 results on Aug 27, 2026
New Risk • Jun 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 97% Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Declared Dividend • Jun 15Dividend increased to CN¥0.13Dividend of CN¥0.13 is 117% higher than last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 79% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Xue Junfu was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29HitGen Inc., Annual General Meeting, May 29, 2026HitGen Inc., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 2F, Building C2, No. 18, Huigu Dongyi Road, Shuangliu District, Chengdu, Sichuan China
お知らせ • Jun 30HitGen Inc. to Report First Half, 2026 Results on Aug 27, 2026HitGen Inc. announced that they will report first half, 2026 results on Aug 27, 2026
New Risk • Jun 28New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 97% Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Declared Dividend • Jun 15Dividend increased to CN¥0.13Dividend of CN¥0.13 is 117% higher than last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 79% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Xue Junfu was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29HitGen Inc., Annual General Meeting, May 29, 2026HitGen Inc., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 2F, Building C2, No. 18, Huigu Dongyi Road, Shuangliu District, Chengdu, Sichuan China
お知らせ • Mar 30HitGen Inc. to Report Q1, 2026 Results on Apr 29, 2026HitGen Inc. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Dec 26HitGen Inc. to Report Fiscal Year 2025 Results on Apr 29, 2026HitGen Inc. announced that they will report fiscal year 2025 results on Apr 29, 2026
お知らせ • Sep 30HitGen Inc. to Report Q3, 2025 Results on Oct 30, 2025HitGen Inc. announced that they will report Q3, 2025 results on Oct 30, 2025
お知らせ • Aug 27HitGen Inc. Introduces OpenDEL™ 5.0HitGen Inc. is raising the bar with the introduction of OpenDEL™ 5.0 - featuring a total of 4 billion diverse compounds designed to tackle challenging biological targets. OpenDEL™ 5.,0 comes in a convenient kit format that is accessible to scientists in industry and academia alike. Key Improvements: Expanded Chemical Diversity: 4 billion Compounds; Increased Library Size: Now with 25% more compounds, OpenDEL™ 5.'0 offers 3.8 billion small molecules compounds and 200 million peptide compounds to further expand chemical space for targeting protein-protein-interactions (PPI). Encompassing Library Design: 59 distinct libraries provide a broad range of chemistries to address different types of targets and discovery challenges; Optional Macrocycle Library: Unlocking Challenging Targets; A dedicated macrocycle library: Available as an add-on, featuring 4-10 amino acids in the ring. Comes with a linear peptide control library; Dual-Kit Flexibility: Choose between OpenDEL™-Small Molecules or OpenDEL™-Macrocycle - or combine both for maximum coverage; Streamlined Workflow & Faster Access; Redesigned protocols: Intuitive visual guides simplify key steps, reducing onboarding time; Expedited delivery: Next-day shipping available to minimize wait time.
お知らせ • Jun 30HitGen Inc. to Report First Half, 2025 Results on Aug 28, 2025HitGen Inc. announced that they will report first half, 2025 results on Aug 28, 2025
お知らせ • Apr 26HitGen Inc., Annual General Meeting, May 23, 2025HitGen Inc., Annual General Meeting, May 23, 2025, at 14:30 China Standard Time. Location: 2F, Building C2, No. 18, Huigu East 1st Road, Shuangliu District, Chengdu, Sichuan China
お知らせ • Mar 28HitGen Inc. to Report Q1, 2025 Results on Apr 26, 2025HitGen Inc. announced that they will report Q1, 2025 results on Apr 26, 2025
お知らせ • Dec 27HitGen Inc. to Report Fiscal Year 2024 Results on Apr 26, 2025HitGen Inc. announced that they will report fiscal year 2024 results on Apr 26, 2025
New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.031 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.031 in 3Q 2023). Revenue: CN¥103.5m (up 15% from 3Q 2023). Net income: CN¥19.9m (up 60% from 3Q 2023). Profit margin: 19% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.
Buy Or Sell Opportunity • Oct 22Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to CN¥12.32. The fair value is estimated to be CN¥10.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 19%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 56% in the next 2 years.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Sep 30HitGen Inc. to Report Q3, 2024 Results on Oct 26, 2024HitGen Inc. announced that they will report Q3, 2024 results on Oct 26, 2024
Buy Or Sell Opportunity • Jul 31Now 20% overvaluedOver the last 90 days, the stock has fallen 24% to CN¥10.30. The fair value is estimated to be CN¥8.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 23%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 1.1% in the next 2 years.
Buy Or Sell Opportunity • Jul 11Now 25% overvaluedOver the last 90 days, the stock has fallen 13% to CN¥10.84. The fair value is estimated to be CN¥8.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 23%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 1.1% in the next 2 years.
お知らせ • Jun 29HitGen Inc. to Report First Half, 2024 Results on Aug 29, 2024HitGen Inc. announced that they will report first half, 2024 results on Aug 29, 2024
お知らせ • Apr 26HitGen Inc., Annual General Meeting, May 22, 2024HitGen Inc., Annual General Meeting, May 22, 2024, at 14:30 China Standard Time. Location: 6F, No. 1166, Jiannan Avenue South Section, Shuangliu District, Chengdu, Sichuan China
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.03 (up from CN¥0.02 loss in 1Q 2023). Revenue: CN¥107.4m (up 54% from 1Q 2023). Net income: CN¥13.9m (up CN¥23.3m from 1Q 2023). Profit margin: 13% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.
お知らせ • Mar 29HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024HitGen Inc. announced that they will report Q1, 2024 results on Apr 25, 2024
Buy Or Sell Opportunity • Mar 21Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at CN¥14.98. The fair value is estimated to be CN¥19.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has declined by 32%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 37% in the next 2 years.
Reported Earnings • Feb 25Full year 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.06 in FY 2022)Full year 2023 results: EPS: CN¥0.11 (up from CN¥0.06 in FY 2022). Revenue: CN¥371.7m (up 13% from FY 2022). Net income: CN¥43.9m (up 74% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in China.
Reported Earnings • Nov 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: CN¥90.1m (up 13% from 3Q 2022). Net income: CN¥12.5m (down 29% from 3Q 2022). Profit margin: 14% (down from 22% in 3Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Life Sciences industry in China.
New Risk • Oct 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.022 (up from CN¥0 in 2Q 2022). Revenue: CN¥86.1m (up 30% from 2Q 2022). Net income: CN¥15.2m (up CN¥15.2m from 2Q 2022). Profit margin: 18% (up from 0% in 2Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in China.
お知らせ • Jun 28HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023HitGen Inc. announced that they will report Q2, 2023 results on Aug 23, 2023
お知らせ • Jun 27HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery ResearchHitGen Inc. has recently launched a newly upgraded version of its OpenDEL™? product, a self-service screening kit for novel molecules. It contains 65% more DEL libraries than the previous version, and with over 3 billion compounds. The 2-cycle and 3-cycle libraries in the kit are designed with excellent drug-like properties. The upgraded OpenDEL™? provides more diverse options with more flexible packages and service models to meet more differentiated user needs. OpenDEL™? is a self-service DNA-encoded library (DEL) kit, which enables users to explore DEL selection campaigns without revealing the target identity. Under the guidance of the manual and operating instructions, users can utilize OpenDEL™? to conduct affinity screening experiments against protein targets in their own laboratories. HitGen can provide upstream and downstream technical support. OpenDEL™? are a fully-open, transparent, small molecule screening kit, featuring complete disclosure of information for molecular structures, building blocks, scaffolds and compound encoding sequences. The users do not need to pay structure disclosure fees, nor compound IP license fees. OpenDEL™? can be widely applied in multiple areas, including drug discovery and AI-ML research. In the drug discovery scenarios, the complete information disclosure of OpenDEL™? can enable efficient and convenient discovery of novel hits and lead compounds. In the AI-ML scenarios, OpenDEL™? can provide a large number of high-quality screening data to facilitate the AI/ML predictive model building, algorithm development and validation, as well as other frontier explorations, thus promoting the AI-driven drug development. Since its release, OpenDEL™? has been widely used and highly recognized by many users from more than 10 countries, including biopharmaceutical companies, AI technology companies, academic institutions and colleges.
Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
